Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death

Ilaria Passacantilli, Valentina Panzeri, Francesca Terracciano, Gianfranco Delle Fave, Claudio Sette, Gabriele Capurso

Research output: Contribution to journalArticle

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and current treatments exert small effects on life expectancy. The most common adjuvant treatment for PDAC is gemcitabine. However, relapse almost invariably occurs and most patients develop metastatic, incurable disease. The aim of the present study was to assess the activity of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) alone or in combination with gemcitabine in PDAC cell lines displaying different degrees of sensitivity to gemcitabine treatment. We evaluated the effects of gemcitabine and nab-paclitaxel and their combination on cell proliferation, death, apoptosis and cell cycle distribution in PDAC cell lines either sensitive to gemcitabine, or with primary or secondary resistance to gemcitabine. Our results indicated that the dose‑response of PDAC cell lines to nab-paclitaxel was similar, regardless of their sensitivity to gemcitabine. In addition, nab-paclitaxel elicited similar cytotoxic effects on a PDAC cell line highly resistant to gemcitabine that was selected after prolonged exposure to the drug. Notably, we found that combined treatment with gemcitabine and nab-paclitaxel exerted additive effects on cell death, even at lower doses of the drugs. The combined treatment caused an increase in cell death by apoptosis and in cell cycle blockage in S phase, as assessed by flow cytometry and western blot analysis of the PARP-1 cleavage. These results revealed that a combined treatment with nab-paclitaxel may overcome resistance to gemcitabine and may represent a valuable therapeutic approach for PDAC.

Original languageEnglish
Pages (from-to)1984-1990
Number of pages7
JournalOncology Reports
Volume39
Issue number4
DOIs
Publication statusPublished - Apr 2018

Fingerprint

gemcitabine
Pancreatic Neoplasms
Nanoparticles
Cell Death
Adenocarcinoma
Therapeutics
Cell Line
Cell Cycle
Albumin-Bound Paclitaxel
Apoptosis

Keywords

  • Adenocarcinoma/drug therapy
  • Albumins/pharmacology
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols/pharmacology
  • Apoptosis/drug effects
  • Carcinoma, Pancreatic Ductal/drug therapy
  • Cell Cycle/drug effects
  • Cell Line, Tumor
  • Cell Proliferation/drug effects
  • Deoxycytidine/adverse effects
  • Drug Resistance, Neoplasm/genetics
  • Gene Expression Regulation, Neoplastic/drug effects
  • Humans
  • Mice
  • Neoplasm Recurrence, Local/drug therapy
  • Paclitaxel/pharmacology
  • Poly (ADP-Ribose) Polymerase-1/genetics
  • Xenograft Model Antitumor Assays

Cite this

Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. / Passacantilli, Ilaria; Panzeri, Valentina; Terracciano, Francesca; Delle Fave, Gianfranco; Sette, Claudio; Capurso, Gabriele.

In: Oncology Reports, Vol. 39, No. 4, 04.2018, p. 1984-1990.

Research output: Contribution to journalArticle

Passacantilli, I, Panzeri, V, Terracciano, F, Delle Fave, G, Sette, C & Capurso, G 2018, 'Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death', Oncology Reports, vol. 39, no. 4, pp. 1984-1990. https://doi.org/10.3892/or.2018.6233
Passacantilli, Ilaria ; Panzeri, Valentina ; Terracciano, Francesca ; Delle Fave, Gianfranco ; Sette, Claudio ; Capurso, Gabriele. / Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. In: Oncology Reports. 2018 ; Vol. 39, No. 4. pp. 1984-1990.
@article{1ee40b9741aa42d9a1a80b53485997ce,
title = "Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and current treatments exert small effects on life expectancy. The most common adjuvant treatment for PDAC is gemcitabine. However, relapse almost invariably occurs and most patients develop metastatic, incurable disease. The aim of the present study was to assess the activity of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) alone or in combination with gemcitabine in PDAC cell lines displaying different degrees of sensitivity to gemcitabine treatment. We evaluated the effects of gemcitabine and nab-paclitaxel and their combination on cell proliferation, death, apoptosis and cell cycle distribution in PDAC cell lines either sensitive to gemcitabine, or with primary or secondary resistance to gemcitabine. Our results indicated that the dose‑response of PDAC cell lines to nab-paclitaxel was similar, regardless of their sensitivity to gemcitabine. In addition, nab-paclitaxel elicited similar cytotoxic effects on a PDAC cell line highly resistant to gemcitabine that was selected after prolonged exposure to the drug. Notably, we found that combined treatment with gemcitabine and nab-paclitaxel exerted additive effects on cell death, even at lower doses of the drugs. The combined treatment caused an increase in cell death by apoptosis and in cell cycle blockage in S phase, as assessed by flow cytometry and western blot analysis of the PARP-1 cleavage. These results revealed that a combined treatment with nab-paclitaxel may overcome resistance to gemcitabine and may represent a valuable therapeutic approach for PDAC.",
keywords = "Adenocarcinoma/drug therapy, Albumins/pharmacology, Animals, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Apoptosis/drug effects, Carcinoma, Pancreatic Ductal/drug therapy, Cell Cycle/drug effects, Cell Line, Tumor, Cell Proliferation/drug effects, Deoxycytidine/adverse effects, Drug Resistance, Neoplasm/genetics, Gene Expression Regulation, Neoplastic/drug effects, Humans, Mice, Neoplasm Recurrence, Local/drug therapy, Paclitaxel/pharmacology, Poly (ADP-Ribose) Polymerase-1/genetics, Xenograft Model Antitumor Assays",
author = "Ilaria Passacantilli and Valentina Panzeri and Francesca Terracciano and {Delle Fave}, Gianfranco and Claudio Sette and Gabriele Capurso",
year = "2018",
month = "4",
doi = "10.3892/or.2018.6233",
language = "English",
volume = "39",
pages = "1984--1990",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death

AU - Passacantilli, Ilaria

AU - Panzeri, Valentina

AU - Terracciano, Francesca

AU - Delle Fave, Gianfranco

AU - Sette, Claudio

AU - Capurso, Gabriele

PY - 2018/4

Y1 - 2018/4

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and current treatments exert small effects on life expectancy. The most common adjuvant treatment for PDAC is gemcitabine. However, relapse almost invariably occurs and most patients develop metastatic, incurable disease. The aim of the present study was to assess the activity of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) alone or in combination with gemcitabine in PDAC cell lines displaying different degrees of sensitivity to gemcitabine treatment. We evaluated the effects of gemcitabine and nab-paclitaxel and their combination on cell proliferation, death, apoptosis and cell cycle distribution in PDAC cell lines either sensitive to gemcitabine, or with primary or secondary resistance to gemcitabine. Our results indicated that the dose‑response of PDAC cell lines to nab-paclitaxel was similar, regardless of their sensitivity to gemcitabine. In addition, nab-paclitaxel elicited similar cytotoxic effects on a PDAC cell line highly resistant to gemcitabine that was selected after prolonged exposure to the drug. Notably, we found that combined treatment with gemcitabine and nab-paclitaxel exerted additive effects on cell death, even at lower doses of the drugs. The combined treatment caused an increase in cell death by apoptosis and in cell cycle blockage in S phase, as assessed by flow cytometry and western blot analysis of the PARP-1 cleavage. These results revealed that a combined treatment with nab-paclitaxel may overcome resistance to gemcitabine and may represent a valuable therapeutic approach for PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and current treatments exert small effects on life expectancy. The most common adjuvant treatment for PDAC is gemcitabine. However, relapse almost invariably occurs and most patients develop metastatic, incurable disease. The aim of the present study was to assess the activity of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) alone or in combination with gemcitabine in PDAC cell lines displaying different degrees of sensitivity to gemcitabine treatment. We evaluated the effects of gemcitabine and nab-paclitaxel and their combination on cell proliferation, death, apoptosis and cell cycle distribution in PDAC cell lines either sensitive to gemcitabine, or with primary or secondary resistance to gemcitabine. Our results indicated that the dose‑response of PDAC cell lines to nab-paclitaxel was similar, regardless of their sensitivity to gemcitabine. In addition, nab-paclitaxel elicited similar cytotoxic effects on a PDAC cell line highly resistant to gemcitabine that was selected after prolonged exposure to the drug. Notably, we found that combined treatment with gemcitabine and nab-paclitaxel exerted additive effects on cell death, even at lower doses of the drugs. The combined treatment caused an increase in cell death by apoptosis and in cell cycle blockage in S phase, as assessed by flow cytometry and western blot analysis of the PARP-1 cleavage. These results revealed that a combined treatment with nab-paclitaxel may overcome resistance to gemcitabine and may represent a valuable therapeutic approach for PDAC.

KW - Adenocarcinoma/drug therapy

KW - Albumins/pharmacology

KW - Animals

KW - Antineoplastic Combined Chemotherapy Protocols/pharmacology

KW - Apoptosis/drug effects

KW - Carcinoma, Pancreatic Ductal/drug therapy

KW - Cell Cycle/drug effects

KW - Cell Line, Tumor

KW - Cell Proliferation/drug effects

KW - Deoxycytidine/adverse effects

KW - Drug Resistance, Neoplasm/genetics

KW - Gene Expression Regulation, Neoplastic/drug effects

KW - Humans

KW - Mice

KW - Neoplasm Recurrence, Local/drug therapy

KW - Paclitaxel/pharmacology

KW - Poly (ADP-Ribose) Polymerase-1/genetics

KW - Xenograft Model Antitumor Assays

U2 - 10.3892/or.2018.6233

DO - 10.3892/or.2018.6233

M3 - Article

C2 - 29393478

VL - 39

SP - 1984

EP - 1990

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -